| 摘要 |
One of the problems in the technical management of boron neutron capture therapy of tumours is the adequate localisation of boron in the target tissue. Such a localisation can be tested successfully if biologically active molecules having a differential affinity for the target tissue are modified with boron compounds such that their activity and affinity are retained. For protein in particular, it is demanded here that the chosen boron compound is stable to hydrolysis and the solubility of the protein is not reduced. B-decachloro-o-carboranyl compounds are suitable for this purpose, since they are polar and charged in physiological pH ranges. They can be bound to proteins without their solubility being reduced.
|
